Company intelligence / Profile preview

Kerecis

Ownership: Private
Employees: ~525
Development stage: Commercial

Overview

Kerecis’ fish-skin grafts are FDA-cleared and CE-marked for use in treating chronic and acute wounds. Clinical results have shown efficacy in promoting wound healing and tissue regeneration across a range of indications including diabetic foot ulcers and burns. The company’s products are used globally with thousands of patients treated.

Therapeutic areas: OtherDermatologyWomen's Health
Modalities: Fish skin-based biologic graftsBiologicMedical Device
Industry: Therapeutic Medical Devices

Drug pipeline

3 assets

MariGen

Commercial

Indications: Wounds, Burns

2 more assets in the full pipeline.

Request access →

Partnerships

US Armed Forces/US military branches for research & supplyCigna insurance coverage partnershipEmerson Collective investor partnership prior to acquisition by Coloplast

Beyond the preview

Go deeper on Kerecis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kerecis.

Explore the full profile